[go: up one dir, main page]

IL153327A0 - 4,5-dihydro-thiazo-2-ylamine derivatives and their use as no-synthase inhibitors - Google Patents

4,5-dihydro-thiazo-2-ylamine derivatives and their use as no-synthase inhibitors

Info

Publication number
IL153327A0
IL153327A0 IL15332701A IL15332701A IL153327A0 IL 153327 A0 IL153327 A0 IL 153327A0 IL 15332701 A IL15332701 A IL 15332701A IL 15332701 A IL15332701 A IL 15332701A IL 153327 A0 IL153327 A0 IL 153327A0
Authority
IL
Israel
Prior art keywords
thiazo
dihydro
synthase inhibitors
ylamine derivatives
ylamine
Prior art date
Application number
IL15332701A
Original Assignee
Hoechst Marion Roussel Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Marion Roussel Inc filed Critical Hoechst Marion Roussel Inc
Publication of IL153327A0 publication Critical patent/IL153327A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/18—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
IL15332701A 2000-06-09 2001-06-07 4,5-dihydro-thiazo-2-ylamine derivatives and their use as no-synthase inhibitors IL153327A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0007396A FR2810036B1 (en) 2000-06-09 2000-06-09 4,5-DIHYDRO-1,3-THIAZOL-2-YLAMINE DERIVATIVES, THEIR PREPARATION AND THE PHAMARCEUTICAL COMPOSITIONS CONTAINING THEM
PCT/FR2001/001759 WO2001093867A1 (en) 2000-06-09 2001-06-07 4,5-dihydro-thiazo-2-ylamine derivatives and their use as no-synthase inhibitors

Publications (1)

Publication Number Publication Date
IL153327A0 true IL153327A0 (en) 2003-07-06

Family

ID=8851133

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15332701A IL153327A0 (en) 2000-06-09 2001-06-07 4,5-dihydro-thiazo-2-ylamine derivatives and their use as no-synthase inhibitors

Country Status (27)

Country Link
EP (1) EP1299103B1 (en)
JP (1) JP4171297B2 (en)
KR (1) KR20030017990A (en)
CN (1) CN1441673A (en)
AP (1) AP2002002707A0 (en)
AT (1) ATE305298T1 (en)
AU (2) AU2001266123B2 (en)
BR (1) BR0111543A (en)
CA (1) CA2411572C (en)
DE (1) DE60113686T2 (en)
DK (1) DK1299103T3 (en)
DZ (1) DZ3366A1 (en)
EA (1) EA200300009A1 (en)
EC (1) ECSP024374A (en)
ES (1) ES2246327T3 (en)
FR (1) FR2810036B1 (en)
HR (1) HRP20020971A2 (en)
HU (1) HUP0300996A3 (en)
IL (1) IL153327A0 (en)
MA (1) MA25815A1 (en)
MX (1) MXPA02012072A (en)
NO (1) NO20025885L (en)
NZ (1) NZ522967A (en)
OA (1) OA12285A (en)
PL (1) PL360282A1 (en)
WO (1) WO2001093867A1 (en)
ZA (1) ZA200209770B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8088935B2 (en) 2003-12-23 2012-01-03 Ironwood Pharmaceuticals, Inc. Compounds and methods for the treatment of asthma

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5533094A (en) * 1992-11-27 1994-06-22 Wellcome Foundation Limited, The Enzyme inhibitors
RU2136661C1 (en) * 1993-10-21 1999-09-10 Джи Ди Сирл энд Ко. Amidino-derivatives, their use and pharmaceutical composition
AU4149696A (en) * 1994-11-15 1996-06-06 Merck & Co., Inc. Substituted heterocycles as inhibitors of nitric oxide synthase

Also Published As

Publication number Publication date
DZ3366A1 (en) 2001-12-13
JP4171297B2 (en) 2008-10-22
NO20025885D0 (en) 2002-12-06
MA25815A1 (en) 2003-07-01
JP2003535135A (en) 2003-11-25
HUP0300996A3 (en) 2006-02-28
ATE305298T1 (en) 2005-10-15
HUP0300996A2 (en) 2003-08-28
ES2246327T3 (en) 2006-02-16
WO2001093867A1 (en) 2001-12-13
OA12285A (en) 2006-05-12
FR2810036A1 (en) 2001-12-14
ZA200209770B (en) 2004-03-02
AP2002002707A0 (en) 2002-12-31
NZ522967A (en) 2005-07-29
EP1299103B1 (en) 2005-09-28
AU6612301A (en) 2001-12-17
HRP20020971A2 (en) 2005-02-28
EP1299103A1 (en) 2003-04-09
NO20025885L (en) 2003-01-29
MXPA02012072A (en) 2004-08-19
FR2810036B1 (en) 2004-04-23
BR0111543A (en) 2003-07-01
CA2411572A1 (en) 2001-12-13
CA2411572C (en) 2009-11-10
PL360282A1 (en) 2004-09-06
ECSP024374A (en) 2003-02-06
CN1441673A (en) 2003-09-10
DK1299103T3 (en) 2006-01-23
KR20030017990A (en) 2003-03-04
DE60113686T2 (en) 2006-07-13
DE60113686D1 (en) 2006-02-09
EA200300009A1 (en) 2003-04-24
AU2001266123B2 (en) 2007-01-25

Similar Documents

Publication Publication Date Title
AU7392101A (en) 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors
SI1686119T1 (en) Pyrimidine-5-one derivatives as LDL-PLA2 inhibitors
MXPA03004794A (en) New mandelic acid derivatives and their use as throbin inhibitors.
AP2003002857A0 (en) New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors.
HK1053124A1 (en) Substituted quinazoline derivatives and their use as inhibitors
HUP0302125A3 (en) Naphthalene derivatives
HUP0203961A3 (en) 3-phenoxy-1-phenyl acetylene derivatives and their use as herbicedes
AU2001244355A1 (en) Heterobiarylsulphonamides and their use as pde 7 inhibitors
GB0031295D0 (en) Naphthalene derivatives
HK1081954A1 (en) Novel 1,4-diazabicycloalkane derivatives, their preparation and use
GB0026467D0 (en) Compound, composition and use
AU2001276027A1 (en) Heteroaryl-beta-alanine derivatives as alpha 4 integrin inhibitors
HK1057900A1 (en) 2-Aminothiazoline derivatives and their use as no-synthase inhibitors.
PL359668A1 (en) Biphenyl derivatives and the use thereof as integrin inhibitors
GB0005301D0 (en) Compound, composition and use
AU7815201A (en) Synthetic salicylihalamides, apicularens and derivatives thereof
AU6612301A (en) 4,5-dihydro-thiazo-2-ylamine derivatives and their use as no-synthase inhibitors
GB0005299D0 (en) Compound, compositions and use
AU2001266123A1 (en) 4,5-dihydro-thiazo-2-ylamine derivatives and their use as no-synthase inhibitors
AU2001282268A1 (en) Phenantridine derivatives and their use as anti-telomerase agent
HK1053059A1 (en) New use of imidazotriazinon derivatives
AU8973201A (en) Biphenyl derivatives and the use thereof as integrin inhibitors
SI1268480T1 (en) 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors
AU2001294910A1 (en) 3-thioxo-(1,2,4)-oxadiazinan-5-one and their use as anti-antherosclerotic agents
SI1244650T1 (en) Arylamine derivatives and their use as anti-telomerase agent